This study is for children aged 6 to 12 years with HIV-1, a virus that attacks the immune system. It tests a new pill combining two drugs, Dolutegravir and Rilpivirine, to see how the body handles it (pharmacokinetics), how safe it is, and if it works well without causing bad side effects (tolerability). To join, kids must weigh at least 25 kilograms and have been on the same HIV medicine for the past six months, with no signs of the virus in their blood.
Key points to consider before participation:
- Study Length: Participation involves 24 weeks of study treatment.
- Visits: Regular visits to the study site are required for monitoring and tests.
- Risks: Possible side effects and drug interactions need to be considered.
Children with a history of certain drug resistances or medical conditions, like liver disease or heart problems, are not eligible. The study aims to find a simpler, effective treatment for young patients with HIV-1.
How understandable was the trial content above?
Hard to understand
Easy to understand